Target ID & Validation

  • Easily develop and perform high throughput target ID screens
  • Characterize a wide variety of analytes from small molecule fragments to biologics



Overview for Target ID & Validation

Identifying and characterizing promising therapeutic targets as an intervention to disease is the first step in the drug discovery process. Recognizing the correct targets from the discovery process is critical through validation before investing further time and resources. Label-free binding technologies such as Bio-Layer Interferometry (BLI) and Surface Plasmon Resonance (SPR) systems are indispensable tools in both discovery and validation processes where high throughput binding screens can be quickly established to identify binding targets and accurately characterize for rates of complex formation (ka), complex stability (ka, dissociation) and affinities (KD).

  • Large molecules kinetics characterization

    The BLI Octet® family of instruments accurately measures kinetic constants by bringing the detection surface directly to the sample, eliminating the need for microfluidics. This unique approach utilizing label-free, real-time analysis streamlines laboratory workflow and expedites assay development. It allows direct measurement of crude samples while minimizing instrument maintenance.

    阅读应用说明  

    Protein - Small molecules and peptide kinetics & affinity characterization

    Small molecule and peptide therapeutic drugs are highly sought after in most areas of disease research due to their desirable pharmacological properties and low propensity for immunogenicity. In small molecule drug discovery, the path to lead molecules can stem from many sources or starting points including fragment screening, high throughput screening, de novo structural design, etc. The determination and evaluation of the affinity of small molecule binding to a therapeutic target is a significant component of the drug discovery process and lead optimization. The hit-to-lead and lead optimization process are essential to accurately determine biological potency in vitro so that structure-activity relationships (SAR) can be used for efficient structural design. Learn how ForteBio BLI Octet RED96e, Octet RED384 , HTX and Pioneer SPR platforms can be used to characterize small molecule and peptide systems.

    阅读应用说明  

Resources for Target ID & Validation

相关产品和服务

准备好了吗?

我们已准备好帮助您解决在研究中遇到的严峻挑战。我们具有遍布全球的经验丰富的专业技术团队,可帮助您实现下一个突破。